Prospective study of TACE combined with sorafenib vs TACE combined with 125I seed implantation in the treatment of hepatocellular carcinoma with portal vein tumor thrombus and arterioportal fistulas
PurposeTo compare the efficacy of TACE combined with sorafenib and TACE combined with 125I seed implantation in the treatment of hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT) combined with arterioportal fistulas (APFs), and discuss the efficacy and safety of TACE combined wit...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-10-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.977462/full |
| _version_ | 1797997275259076608 |
|---|---|
| author | Xiao-Hui Zhao Hang Yuan Wei-Li Xia Li-Lin Zhang Zhen Li Guang-Shao Cao Hai-Liang Li Wei-Jun Fan Hong-Le Li Chen-Yang Guo Quan-Jun Yao Wen-Bo Zhu Hong-Tao Hu |
| author_facet | Xiao-Hui Zhao Hang Yuan Wei-Li Xia Li-Lin Zhang Zhen Li Guang-Shao Cao Hai-Liang Li Wei-Jun Fan Hong-Le Li Chen-Yang Guo Quan-Jun Yao Wen-Bo Zhu Hong-Tao Hu |
| author_sort | Xiao-Hui Zhao |
| collection | DOAJ |
| description | PurposeTo compare the efficacy of TACE combined with sorafenib and TACE combined with 125I seed implantation in the treatment of hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT) combined with arterioportal fistulas (APFs), and discuss the efficacy and safety of TACE combined with 125I seed implantation.Patients and methodsBetween January 2017 and December 2018, the clinical data of patients with HCC complicated with PVTT and APFs who were admitted to the Affiliated Cancer Hospital of Zhengzhou University, First Affiliated Hospital of Zhengzhou University, and Henan Provincial People’s Hospital were prospectively collected. The patients were divided into the TACE+sorafenib (TACE-S) group based on their treatment willingness. There were 26 and 32 patients in the TACE-S and TACE-125I groups, respectively. Both groups of patients underwent APFs occlusion during TACE therapy. The embolization effect of APFs was observed and recorded in the two groups, the efficacy of intrahepatic lesions and PVTT was evaluated, and the effects of different treatment methods on the efficacy were analysed.ResultsAll patients completed the 3 months follow-up. The improvement rates of APFs in TACE-S and TACE-125I groups were 30.77% (8/26) and 68.75% (22/32), respectively, and difference was statistically significant (χ2 = 8.287, P=0.004). The median survival time of TACE-S and TACE-125I groups was 8.00 months and 12.8 months, respectively (χ2 = 7.106, P=0.008). Multivariate analysis showed that the PVTT subtype (IIa/IIb) and treatment method (TACE-S or TACE-125I) were independent factors affecting the recanalization of APFs in patients (P<0.05).ConclusionFor patients with HCC with PVTT and APFs, TACE combined with 125I seed implantation can effectively treat portal vein tumor thrombus, thereby reducing the recanalization of APFs and prolonging the survival time of patients. |
| first_indexed | 2024-04-11T10:30:25Z |
| format | Article |
| id | doaj.art-7c5f04a5b29d47c580a1fac3fea61c35 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-04-11T10:30:25Z |
| publishDate | 2022-10-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-7c5f04a5b29d47c580a1fac3fea61c352022-12-22T04:29:26ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2022-10-011210.3389/fonc.2022.977462977462Prospective study of TACE combined with sorafenib vs TACE combined with 125I seed implantation in the treatment of hepatocellular carcinoma with portal vein tumor thrombus and arterioportal fistulasXiao-Hui Zhao0Hang Yuan1Wei-Li Xia2Li-Lin Zhang3Zhen Li4Guang-Shao Cao5Hai-Liang Li6Wei-Jun Fan7Hong-Le Li8Chen-Yang Guo9Quan-Jun Yao10Wen-Bo Zhu11Hong-Tao Hu12Department of Minimal-Invasive Intervention, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, ChinaDepartment of Minimal-Invasive Intervention, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, ChinaDepartment of Minimal-Invasive Intervention, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, ChinaYangtze University Health Science Center, Jingzhou, ChinaDepartment of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, ChinaDepartment of Intervention, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, Zhengzhou, ChinaDepartment of Minimal-Invasive Intervention, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, ChinaImaging and Interventional Department, Sun Yat-sen University Cancer Center, Guangzhou, ChinaThe Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, ChinaDepartment of Minimal-Invasive Intervention, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, ChinaDepartment of Minimal-Invasive Intervention, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, ChinaDepartment of Minimal-Invasive Intervention, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, ChinaDepartment of Minimal-Invasive Intervention, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, ChinaPurposeTo compare the efficacy of TACE combined with sorafenib and TACE combined with 125I seed implantation in the treatment of hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT) combined with arterioportal fistulas (APFs), and discuss the efficacy and safety of TACE combined with 125I seed implantation.Patients and methodsBetween January 2017 and December 2018, the clinical data of patients with HCC complicated with PVTT and APFs who were admitted to the Affiliated Cancer Hospital of Zhengzhou University, First Affiliated Hospital of Zhengzhou University, and Henan Provincial People’s Hospital were prospectively collected. The patients were divided into the TACE+sorafenib (TACE-S) group based on their treatment willingness. There were 26 and 32 patients in the TACE-S and TACE-125I groups, respectively. Both groups of patients underwent APFs occlusion during TACE therapy. The embolization effect of APFs was observed and recorded in the two groups, the efficacy of intrahepatic lesions and PVTT was evaluated, and the effects of different treatment methods on the efficacy were analysed.ResultsAll patients completed the 3 months follow-up. The improvement rates of APFs in TACE-S and TACE-125I groups were 30.77% (8/26) and 68.75% (22/32), respectively, and difference was statistically significant (χ2 = 8.287, P=0.004). The median survival time of TACE-S and TACE-125I groups was 8.00 months and 12.8 months, respectively (χ2 = 7.106, P=0.008). Multivariate analysis showed that the PVTT subtype (IIa/IIb) and treatment method (TACE-S or TACE-125I) were independent factors affecting the recanalization of APFs in patients (P<0.05).ConclusionFor patients with HCC with PVTT and APFs, TACE combined with 125I seed implantation can effectively treat portal vein tumor thrombus, thereby reducing the recanalization of APFs and prolonging the survival time of patients.https://www.frontiersin.org/articles/10.3389/fonc.2022.977462/fullhepatocellular carcinomaarterioportal fistulasportal vein tumor thrombus125 I seedtransarterial chemoembolizationsorafenib |
| spellingShingle | Xiao-Hui Zhao Hang Yuan Wei-Li Xia Li-Lin Zhang Zhen Li Guang-Shao Cao Hai-Liang Li Wei-Jun Fan Hong-Le Li Chen-Yang Guo Quan-Jun Yao Wen-Bo Zhu Hong-Tao Hu Prospective study of TACE combined with sorafenib vs TACE combined with 125I seed implantation in the treatment of hepatocellular carcinoma with portal vein tumor thrombus and arterioportal fistulas Frontiers in Oncology hepatocellular carcinoma arterioportal fistulas portal vein tumor thrombus 125 I seed transarterial chemoembolization sorafenib |
| title | Prospective study of TACE combined with sorafenib vs TACE combined with 125I seed implantation in the treatment of hepatocellular carcinoma with portal vein tumor thrombus and arterioportal fistulas |
| title_full | Prospective study of TACE combined with sorafenib vs TACE combined with 125I seed implantation in the treatment of hepatocellular carcinoma with portal vein tumor thrombus and arterioportal fistulas |
| title_fullStr | Prospective study of TACE combined with sorafenib vs TACE combined with 125I seed implantation in the treatment of hepatocellular carcinoma with portal vein tumor thrombus and arterioportal fistulas |
| title_full_unstemmed | Prospective study of TACE combined with sorafenib vs TACE combined with 125I seed implantation in the treatment of hepatocellular carcinoma with portal vein tumor thrombus and arterioportal fistulas |
| title_short | Prospective study of TACE combined with sorafenib vs TACE combined with 125I seed implantation in the treatment of hepatocellular carcinoma with portal vein tumor thrombus and arterioportal fistulas |
| title_sort | prospective study of tace combined with sorafenib vs tace combined with 125i seed implantation in the treatment of hepatocellular carcinoma with portal vein tumor thrombus and arterioportal fistulas |
| topic | hepatocellular carcinoma arterioportal fistulas portal vein tumor thrombus 125 I seed transarterial chemoembolization sorafenib |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2022.977462/full |
| work_keys_str_mv | AT xiaohuizhao prospectivestudyoftacecombinedwithsorafenibvstacecombinedwith125iseedimplantationinthetreatmentofhepatocellularcarcinomawithportalveintumorthrombusandarterioportalfistulas AT hangyuan prospectivestudyoftacecombinedwithsorafenibvstacecombinedwith125iseedimplantationinthetreatmentofhepatocellularcarcinomawithportalveintumorthrombusandarterioportalfistulas AT weilixia prospectivestudyoftacecombinedwithsorafenibvstacecombinedwith125iseedimplantationinthetreatmentofhepatocellularcarcinomawithportalveintumorthrombusandarterioportalfistulas AT lilinzhang prospectivestudyoftacecombinedwithsorafenibvstacecombinedwith125iseedimplantationinthetreatmentofhepatocellularcarcinomawithportalveintumorthrombusandarterioportalfistulas AT zhenli prospectivestudyoftacecombinedwithsorafenibvstacecombinedwith125iseedimplantationinthetreatmentofhepatocellularcarcinomawithportalveintumorthrombusandarterioportalfistulas AT guangshaocao prospectivestudyoftacecombinedwithsorafenibvstacecombinedwith125iseedimplantationinthetreatmentofhepatocellularcarcinomawithportalveintumorthrombusandarterioportalfistulas AT hailiangli prospectivestudyoftacecombinedwithsorafenibvstacecombinedwith125iseedimplantationinthetreatmentofhepatocellularcarcinomawithportalveintumorthrombusandarterioportalfistulas AT weijunfan prospectivestudyoftacecombinedwithsorafenibvstacecombinedwith125iseedimplantationinthetreatmentofhepatocellularcarcinomawithportalveintumorthrombusandarterioportalfistulas AT hongleli prospectivestudyoftacecombinedwithsorafenibvstacecombinedwith125iseedimplantationinthetreatmentofhepatocellularcarcinomawithportalveintumorthrombusandarterioportalfistulas AT chenyangguo prospectivestudyoftacecombinedwithsorafenibvstacecombinedwith125iseedimplantationinthetreatmentofhepatocellularcarcinomawithportalveintumorthrombusandarterioportalfistulas AT quanjunyao prospectivestudyoftacecombinedwithsorafenibvstacecombinedwith125iseedimplantationinthetreatmentofhepatocellularcarcinomawithportalveintumorthrombusandarterioportalfistulas AT wenbozhu prospectivestudyoftacecombinedwithsorafenibvstacecombinedwith125iseedimplantationinthetreatmentofhepatocellularcarcinomawithportalveintumorthrombusandarterioportalfistulas AT hongtaohu prospectivestudyoftacecombinedwithsorafenibvstacecombinedwith125iseedimplantationinthetreatmentofhepatocellularcarcinomawithportalveintumorthrombusandarterioportalfistulas |